Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep;20(6):794-799.
doi: 10.1111/pedi.12872. Epub 2019 Jun 13.

Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes

Gianluca Musolino  1 , Klemen Dovc  2 , Charlotte K Boughton  1 , Martin Tauschmann  1   3   4 , Janet M Allen  1   3 , Katrin Nagl  4 , Maria Fritsch  4 , James Yong  5 , Emily Metcalfe  5 , Dominique Schaeffer  6 , Muriel Fichelle  6 , Ulrike Schierloh  6 , Alena G Thiele  7 , Daniela Abt  8 , Harald Kojzar  9 , Julia K Mader  9 , Sonja Slegtenhorst  10 , Nicole Ashcroft  1 , Malgorzata E Wilinska  1   3 , Judy Sibayan  11 , Nathan Cohen  11 , Craig Kollman  11 , Sabine E Hofer  8 , Elke Fröhlich-Reiterer  12 , Thomas M Kapellen  7 , Carlo L Acerini  3 , Carine de Beaufort  6   13 , Fiona Campbell  5 , Birgit Rami-Merhar  4 , Roman Hovorka  1   3 ; Kidsap Consortium
Affiliations
Randomized Controlled Trial

Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes

Gianluca Musolino et al. Pediatr Diabetes. 2019 Sep.

Abstract

Objective: To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day-and-night hybrid closed-loop insulin delivery.

Methods: Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed-loop experience survey following two 3-week periods of unrestricted day-and-night hybrid closed-loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed-loop technology were explored.

Results: Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed-loop. Ninety percent of the responders felt less worried about their child's glucose control using closed-loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets.

Conclusions: Parents/caregivers of very young children reported important quality of life benefits associated with using closed-loop, supporting adoption of this technology in this population.

Keywords: artificial pancreas; closed-loop insulin delivery; type 1 diabetes; very young children.

PubMed Disclaimer

Conflict of interest statement

M.T. reports having received speaker honoraria from Minimed Medtronic and Novo Nordisk. M.Fr. has received speaker honoraria from Minimed Medtronic and has served on advisory boards for Eli Lilly. J.K.M. is a member in the advisory board of Becton‐Dickinson, Boehringer Ingelheim, Eli Lilly, Medtronic and Sanofi, and has received speaker honoraria from Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Nintamed, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier, and Takeda. M.E.W. has received license fees from Becton‐Dickinson and has served as a consultant to Beckton‐Dickinson. S.E.H. declares speaker honoraria from Eli Lilly and Sanofi. E.F.R. reports having received speaker honoraria from Minimed Medtronic and Eli Lilly, serving on advisory boards for Eli Lilly. T.M.K. has received speaker honoraria from Minimed Medtronic, Roche, and Eli Lilly and is member of an advisory board for Abbott Diabetes Care. C.dB. has received speaker honoraria from Minimed Medtronic, and is member of their European Psychology Advisory Board. F.C. does attend Advisory Boards and obtain speaking fees for Abbott, Medtronic, Lilly, and NovoNordisk. B.R.M. reports having received speaker honoraria from Minimed Medtronic, Eli Lilly, Roche, Menarini, and Novo Nordisk, serving on advisory boards for Eli Lilly. R.H. reports having received speaker honoraria from Minimed Medtronic, Eli Lilly, BBraun, and Novo Nordisk, serving on advisory panel for Eli Lilly, receiving license fees from BBraun and Medtronic; and having served as a consultant to BBraun, Sanofi‐Aventis, and Profil. R.H. and M.E.W. report patents and patent applications. G.M., K.D., C.B., J.M.A., K.N., J.Y., E.M., D.S., M.Fi., U.S., A.G.T., D.A., H.K., S.S., N.A., J.S., N.C., C.K., and C.L.A. declare no competing financial interests exist.

References

    1. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population‐based sample of children and adolescents with IDDM. Diabetes Care. 1997;20(1):22‐25. - PubMed
    1. Monaghan MC, Hilliard ME, Cogen FR, Streisand R. Nighttime caregiving behaviors among parents of young children with type 1 diabetes: associations with illness characteristics and parent functioning. Fam Syst Health. 2009;27(1):28‐38. - PubMed
    1. Tupola S, Rajantie J, Akerblom HK. Experience of severe hypoglycaemia may influence both patient's and physician's subsequent treatment policy of insulin‐dependent diabetes mellitus. Eur J Pediatr. 1998;157(8):625‐627. - PubMed
    1. Tauschmann M, Allen JM, Nagl K, et al. Home use of day and night hybrid closed loop insulin delivery in very young children: a multicenter 3‐week, randomized trial. Diabetes Care. 2019;42(4):594‐600. 10.2337/dc18-1881. - DOI - PubMed
    1. Farrington C. Psychosocial impacts of hybrid closed‐loop systems in the management of diabetes: a review. Diabet Med. 2018;35(4):436‐449. - PubMed

Publication types

MeSH terms